RxDoctor Payments Data

Jennifer Trujillo, PA

Physician Assistant · Belen, NMNPI 1609883651

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 119 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$559
  • Amarin Pharma, Inc.$199
  • Pfizer$182
  • Lilly USA, LLC$172
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$94
  • Aimmune Therapeutics, Inc.$91
  • plus $459 from 12 others

What the payments were for

  • Food & beverage$1,756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,756 in reported general payments places this provider in the 85th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$55,857
Medicare patients
121
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide155$180,688
MounjaroTirzepatide46$49,228
TrulicityDulaglutide45$45,641
JardianceEmpagliflozin30$29,560
EliquisApixaban25$25,598
MyrbetriqMirabegron33$21,919
FarxigaDapagliflozin Propanediol14$14,173
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$12,460
JanuviaSitagliptin Phosphate13$12,124
LinzessLinaclotide14$7,407
Tresiba Flextouch U-100Insulin Degludec11$5,426
Incruse ElliptaUmeclidinium Bromide11$4,745
Humalog Kwikpen U-100Insulin Lispro13$4,659
SymbicortBudesonide/Formoterol Fumarate18$4,183
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$67$180,688155 claims
Lilly USA, LLCMounjaro, Trulicity$172$94,86991 claims
PfizerEliquis$182$25,59825 claims
AstraZenecaFarxiga, Symbicort$78$18,35632 claims
AbbVieLinzess$559$7,40714 claims
GSKIncruse Ellipta$27$4,74511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Belen

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →